Top in cardiology: Preterm delivery and CHD, danicamtiv improves heart function

Researchers have identified a link between preterm delivery and future maternal risk for ischemic heart disease. It was the top story in cardiology last week.

Another top story was about a trial that described how the novel therapy danicamtiv (MyoKardia) improved outcomes among certain patients with heart failure.

Read more on these and other top stories in cardiology below:

Preterm delivery increases lifetime risk for ischemic heart disease

Women who delivered babies earlier than 37 weeks had an increased risk for ischemic heart disease throughout their lifetime, researchers found. Read more.

Novel cardiac myosin activator improves left ventricular contractility in heart failure with reduced ejection fraction

Danicamtiv, a novel cardiac myosin activator, improved left ventricular systolic function and left atrial volume and function for patients with heart failure with reduced ejection fraction in a phase 2a trial. Read more.

Q&A: Navigating drug interactions crucial in patients with atrial fibrillation, COVID-19

To help guide the teams who are navigating how best to treat COVID-19, a new document was published in the Journal of the American Heart Association with a detailed framework for predicting the interactions of antiarrhythmic drugs and medications being used to treat patients with COVID-19. Read more.

Insertable Bluetooth arrhythmia monitoring system nets FDA clearance

Boston Scientific announced it received clearance from the FDA for the company’s new insertable cardiac monitor system. Read more.

Long-term sugar intake increases ectopic fat depots

Increased intake of added sugar and sugar-sweetened beverages was linked to greater visceral and pericardial adipose tissue volumes, researchers found. Read more.